Estònia - estonià - Adama

adama - suspo-emulsioon - 2.4d + florasulaam - herbitsiidid

Estònia - estonià - Adama

adama - emulsioonikontsentraat - propakvisafop - herbitsiidid

Estònia - estonià - Adama

adama - suspo-emulsioon - florasulaam + fluroksüpüür - herbitsiidid

Estònia - estonià - Adama

adama - suspensioonikontsentraat - diflufenikaan + kloortoluroon + pendimetaliin - herbitsiidid

Estònia - estonià - Adama

adama - emulsioonikontsentraat - kvisalofop-p-etüül - herbitsiidid

Estònia - estonià - Adama

adama - suspensioonikontsentraat - kvinmerak + metasakloor - herbitsiidid

Unió Europea - estonià - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastilised ained - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

Estònia - estonià - Ravimiamet

medochemie limited - lakosamiid - õhukese polümeerikattega tablett - 100mg 14tk; 100mg 56tk; 100mg 7tk; 100mg 168tk

Estònia - estonià - Ravimiamet

medochemie limited - lakosamiid - õhukese polümeerikattega tablett - 50mg 14tk; 50mg 28tk; 50mg 168tk; 50mg 56tk

Estònia - estonià - Ravimiamet

medochemie limited - lakosamiid - õhukese polümeerikattega tablett - 150mg 56tk; 150mg 168tk; 150mg 28tk; 150mg 14tk